Research programme: Alzheimer's disease vaccines - Pharmexa/Lundbeck

Drug Profile

Research programme: Alzheimer's disease vaccines - Pharmexa/Lundbeck

Alternative Names: Alzheimer's-disease-vaccine; ME 106; PX106

Latest Information Update: 21 Dec 2007

Price : $50

At a glance

  • Originator Pharmexa
  • Class Alzheimer vaccines; Antidementias; Neuroprotectants; Vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 14 Dec 2007 Lundbeck and Pharmexa extend and update their license agreement
  • 14 Dec 2007 Preclinical development is ongoing in Denmark
  • 25 Nov 2005 This programme is still in active development for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top